Drug Trial Radar · NCT07818070
A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Feb 2027
Primary completion
Jan 2031
Study completion Jan 2031
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Deciphera Pharmaceuticals, LLC
- First posted
- Sep 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of ONO-4578 in combination nivolumab and chemotherapy in participants with advanced or metastatic gastric cancer, esophagogastric junction cancer, or esophageal adenocarcinoma. Participants will: * Receive either ONO-4578 with nivolumab and chemotherapy or placebo with nivolumab and chemotherapy. * Make visits to the clinic for checkups and tests. * Answer questions about their health throughout the trial.
Conditions
- Gastric Cancer
- Esophagogastric Junction Cancer
- Esophageal Adenocarcinoma
Interventions
ONO-4578Drug
ONO-4578 will be administered to participants at a specified dose once daily.
PlaceboOther
Matching placebo for ONO-4578 will be administered to participants once daily.
NivolumabDrug
Nivolumab will be administered to participants at a specified dose on specified days.
OxaliplatinDrug
Oxaliplatin will be administered to participants at a specified dose on specified days.
CapecitabineDrug
Capecitabine will be administered to participants at a specified dose on specified days.
Tegafur-gimeracil-oteracil potassium (S-1)Drug
S-1 will be administered to participants at a specified dose on specified days.
FluorouracilDrug
Fluorouracil will be administered to participants at a specified dose on specified days.
Leucovorin CalciumDrug
Leucovorin Calcium will be administered to participants at a specified dose on specified days.
LevoleucovorinDrug
Levoleucovorin will be administered to participants at a specified dose on specified days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 4 years
- Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR)Time frame: Up to approximately 4 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.